(Stroke. 1995;26:749-754.)
© 1995 American Heart Association, Inc.
Articles |
Anticardiolipin Antibodies in Normal Subjects
Neuropsychological Correlates and MRI Findings
From the Departments of Neurology (R.S., F.F., H.O., P.K.) and Dermatology (P.A.-G.) and the MRI Center (R.S., F.F., H.O., P.K.), Karl Franzens University Graz (Austria).
Correspondence to Reinhold Schmidt, MD, Department of Neurology, Karl-Franzens University Graz, Auenbruggerplatz 22, A-8036 Graz, Austria.
Background and Purpose Our aim was to assess the association of elevated anticardiolipin antibody (aCL) titers with silent brain damage and cognitive functioning in middle-aged and elderly normal subjects.
Methods We determined the IgM and IgG aCL titers from 233 randomly selected clinically normal participants of a population-based stroke prevention study (age range, 44 to 82 years). aCL titers were categorized into negative (0 to 10 U/L), low positive (10 to 20 U/L), and moderately high positive (>20 U/L). All participants underwent 1.5-T MRI and demanding neuropsychological testing. Semiautomated measurements of the total white matter hyperintensity area and the size of ventricles and cortical sulci were conducted.
Results There were 180 subjects (77.3%) with negative, 35 (15.0%) with low positive, and 18 (7.7%) with moderately high positive aCL titers. The frequency and extent of focal and diffuse brain abnormalities were not related to the aCL status of those examined. However, subjects with positive aCL results performed worse than those with negative findings on almost all tests administered, and this effect was mainly IgG titer related. When an ANCOVA test and partial correlations to correct for slight group differences in age and for the presence of major vascular risk factors were used, values of P<.05 were noted on tests assessing mnemonic and visuopractical abilities.
Conclusions Increased aCL titers in normal elderly persons may be associated with subtle neuropsychological dysfunction, but they do not appear to cause any morphological changes as demonstrated by MRI.
Key Words: aging • anticoagulants, anticardiolipin antibodies • neuropsychology • magnetic resonance imaging
This article has been cited by other articles:
 |
|
 |
|
  M. G. Bouwhuis, S. Suciu, S. Collette, S. Aamdal, W. H. Kruit, L. Bastholt, U. Stierner, F. Sales, P. Patel, C. J. A. Punt, et al. Autoimmune Antibodies and Recurrence-Free Interval in Melanoma Patients Treated With Adjuvant Interferon J Natl Cancer Inst, June 16, 2009; 101(12): 869 - 877. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Tektonidou, N. Varsou, G. Kotoulas, A. Antoniou, and H. M. Moutsopoulos Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings. Arch Intern Med, November 13, 2006; 166(20): 2278 - 2284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Sastre-Garriga and X Montalban APS and the brain Lupus, December 1, 2003; 12(12): 877 - 882. [Abstract] [PDF]
|
|
|
|
|
|
S D Denburg and J A Denburg Cognitive dysfunction and antiphospholipid antibodies in systemic lupus erythematosus Lupus, December 1, 2003; 12(12): 883 - 890. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Kapeller, R. Barber, R.J. Vermeulen, H. Ader, P. Scheltens, W. Freidl, O. Almkvist, M. Moretti, T. del Ser, P. Vaghfeldt, et al. Visual Rating of Age-Related White Matter Changes on Magnetic Resonance Imaging: Scale Comparison, Interrater Agreement, and Correlations With Quantitative Measurements Stroke, February 1, 2003; 34(2): 441 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Goldstein, R. Adams, K. Becker, C. D. Furberg, P. B. Gorelick, G. Hademenos, M. Hill, G. Howard, V. J. Howard, B. Jacobs, et al. Primary Prevention of Ischemic Stroke : A Statement for Healthcare Professionals From the Stroke Council of the American Heart Association Circulation, January 2, 2001; 103(1): 163 - 182. [Full Text] [PDF]
|
|
|
|
|
|
L. B. Goldstein, R. Adams, K. Becker, C. D. Furberg, P. B. Gorelick, G. Hademenos, M. Hill, G. Howard, V. J. Howard, B. Jacobs, et al. Primary Prevention of Ischemic Stroke : A Statement for Healthcare Professionals From the Stroke Council of the American Heart Association Stroke, January 1, 2001; 32(1): 280 - 299. [Full Text] [PDF]
|
|
|
|
|
|
A. Sabet, W. L. Sibbitt Jr, C. A. Stidley, J. Danska, and W. M. Brooks Neurometabolite Markers of Cerebral Injury in the Antiphospholipid Antibody Syndrome of Systemic Lupus Erythematosus Stroke, November 1, 1998; 29(11): 2254 - 2260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E Hachulla, U Michon-Pasturel, D Leys, J-P Pruvo, V Queyrel, E Masy, J Arvieux, C Caron, F Brevet-Coupee, P-Y Hatron, et al. Cerebral magnetic resonance imaging in patients with or without antiphospholipid antibodies Lupus, February 1, 1998; 7(2): 124 - 131. [Abstract] [PDF]
|
|
|
|
|
|
R. Brey and A. Escalante Review : Neurological manifestations of antiphospholipid antibody syndrome Lupus, January 1, 1998; 7(2_suppl): S67 - S74. [Abstract] [PDF]
|
|